(redirected from graft-versus-host disease)
Also found in: Dictionary, Medical, Legal, Encyclopedia, Wikipedia.
Related to graft-versus-host disease: cGVHD
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for disease

Synonyms for disease

a pathological condition of mind or body

Words related to disease

References in periodicals archive ?
US-based Incyte has treated its first patient in a phase three trial named Gravitas-301 for the first-line treatment of patients with acute graft-versus-host disease (GVHD), it was reported on Friday.
Graft-versus-host disease is a condition that might occur after an allogeneic transplant (the transfer of genetically dissimilar stem cells or tissue).
2012) How we treat oral chronic graft-versus-host disease.
Naive and memory T cells induce different types of graft-versus-host disease.
Liver transplant-associated graft-versus-host disease.
Six patients died during follow-up, one from cytomegalovirus pneumonia, one from progressive disease due at least in part to a delay between the autograft and the allograft because of insurance problems, one from encephalopathy and three from acute graft-versus-host disease.
Graft-versus-host disease of the skin, liver, and digestive tract developed in a 39-year-old woman with chronic myelogenous leukemia after an allogeneic hematopoietic stem cell transplant in September 1995, during which she was treated with cyclosporine and high-dose prednisolone.
The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT.
M2 EQUITYBITES-October 20, 2016-Alexion Pharmaceuticals Inc passes US FDA orphan drug designation for ALXN1007 for treating graft-versus-host disease (GVHD)
Cynata Therapeutics, an Australia-based stem cell and regenerative medicine company, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to go ahead with its phase one clinical trial of CYP-001 in patients with steroid-resistant graft-versus-host disease, it was reported yesterday.
OTCQB:ENDV), said it is developing a treatment for Graft-versus-Host Disease (GvHD) using Cytotronics expanded and ex vivo enhanced stem cells from the human umbilical cord.
The company said it has taken its method of expanding a population of immune privileged stem cells from the human umbilical cord and combined it with the Cytotronics platform to create large quantities of optimized immuno-regulatory stem cells that can be used as an allogeneic, off-the-shelf therapy for the treatment of Graft-versus-Host Disease.
Graft-versus-host disease is a complication of bone marrow transplants that can cause problems including skin rash, shortness of breath, abdominal pain, jaundice and muscle weakness.
August 7, 2013 -- Researchers have identified and validated a biomarker accessible in blood tests that could be used to predict which stem cell transplant patients are at highest risk for a potentially fatal immune response called graft-versus-host disease.
That's because marrow delivers more than just nascent blood cells; it carries mature immune cells that can make trouble by attacking a recipient's tissues, causing graft-versus-host disease.